Sugi Predict

Sugi Predict / Compounds / SCHEMBL20181615

SCHEMBL20181615

SCHEMBL20181615

CCc1nc2ncccn2c1C(=O)c1cc(Br)c(O)c(Br)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.47
▸ HPGD P15428 7/20 0.47
▸ KDM4E B2RXH2 5/20 0.47
▸ HSD17B10 Q99714 3/20 0.47
▸ SLC22A12 Q96S37 9/20 0.40
▸ GAA P10253 1/20 0.39
▸ EYA3 Q99504 3/20 0.37
▸ TTR P02766 3/20 0.37
▸ CYP2C9 P11712 2/20 0.37
▸ EYA2 O00167 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ ABCC4 O15439 1/20 0.37
▸ PLIN1 O60240 1/20 0.37
▸ NR1I2 O75469 1/20 0.37
▸ USP2 O75604 1/20 0.37
▸ ABCB11 O95342 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ ALB P02768 1/20 0.37
▸ ESR1 P03372 1/20 0.37
▸ NR3C1 P04150 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21192148 0.90 ALDH1A1 (0.41) ALDH1A1HPGDKDM4EHSD17B10SLC22A12
SCHEMBL29638926 0.90 ALDH1A1 (0.41) ALDH1A1HPGDKDM4EHSD17B10SLC22A12
SCHEMBL21176890 0.90 ALDH1A1 (0.47) ALDH1A1HPGDKDM4EHSD17B10SLC22A12
SCHEMBL20181614 0.82 ALDH1A1 (0.50) ALDH1A1HPGDKDM4EHSD17B10SLC22A12
SCHEMBL22612506 0.81 SLC22A12 (0.37) ALDH1A1HPGDHSD17B10SLC22A12EYA3
SCHEMBL21192218 0.81 SLC22A12 (0.37) ALDH1A1HPGDKDM4EHSD17B10SLC22A12
SCHEMBL29638912 0.81 ALDH1A1 (0.49) ALDH1A1HPGDKDM4EHSD17B10GAA
SCHEMBL21176893 0.81 ALDH1A1 (0.49) ALDH1A1HPGDKDM4EHSD17B10GAA
SCHEMBL21191873 0.81 SLC22A12 (0.36) ALDH1A1HPGDHSD17B10SLC22A12EYA3
SCHEMBL18629839 0.80 MAPK1 (0.46) ALDH1A1HPGDKDM4EHSD17B10SLC22A12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE50083-E1 URAT1 inhibitor and use thereof JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2024-08-20 — — US claimed
CN-117586272-A Heterocyclic compound, preparation method and application thereof in medicine 苏州信诺维医药科技股份有限公司 2024-02-23 — — CN claimed
EP-3543240-B1 URAT1 INHIBITOR AND USE THEREOF JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) 2022-07-06 — — EP claimed
CN-108084186-B URAT1 inhibitor and application thereof 江苏新元素医药科技有限公司 2021-06-25 — — CN claimed
CN-112979661-A Heterocyclic compound, preparation method and application thereof in medicine 苏州信诺维医药科技有限公司 2021-06-18 — — CN claimed
US-10875865-B2 URAT1 inhibitor and use thereof JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2020-12-29 — — US claimed
CN-111615515-A Heterocyclic compound, preparation method and application thereof in medicine 苏州信诺维医药科技有限公司 2020-09-01 — — CN claimed
US-20200062763-A1 URAT1 INHIBITOR AND USE THEREOF JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2020-02-27 — — US claimed
EP-3543240-A1 URAT1 INHIBITOR AND USE THEREOF Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. (CN) 2019-09-25 — — EP claimed
US-RE50083-E1 URAT1 inhibitor and use thereof JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2024-08-20 — — US disclosed
CN-117586272-A Heterocyclic compound, preparation method and application thereof in medicine 苏州信诺维医药科技股份有限公司 2024-02-23 — — CN disclosed
CN-111615515-B Heterocyclic compound, preparation method and application thereof in medicine 苏州信诺维医药科技股份有限公司 2023-11-24 — — CN disclosed
EP-3741759-B1 IMIDAZO[1,2-A]PYRIMIDINE AND IMIDAZO[1,2-C]PYRIMIDINE COMPOUNDS AND USE THEREOF IN THE TREATMENT OF HYPERURICEMIA AND GOUT EVOPOINT BIOSCIENCES CO LTD (CN) 2023-08-23 — — EP disclosed
US-11453674-B2 Heterocyclic compound, preparation method and use thereof in medicine Evopoint Biosciences Co., Ltd. (CN) 2022-09-27 — — US disclosed
US-20200347070-A1 HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF IN MEDICINE SHANGHAI PUCHI BIOMEDICAL CO., LTD. (CN) 2020-11-05 — — US disclosed
CN-111615515-A Heterocyclic compound, preparation method and application thereof in medicine 苏州信诺维医药科技有限公司 2020-09-01 — — CN disclosed
US-20200062763-A1 URAT1 INHIBITOR AND USE THEREOF JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2020-02-27 — — US disclosed
EP-3543240-A1 URAT1 INHIBITOR AND USE THEREOF Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. (CN) 2019-09-25 — — EP disclosed
EP-3543240-A1 URAT1 INHIBITOR AND USE THEREOF Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. (CN) 2019-09-25 — — EP disclosed
WO-2018090921-A1 URAT1 INHIBITOR AND USE THEREOF 江苏新元素医药科技有限公司 2018-05-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11453674-B2 Heterocyclic compound, preparation method and use thereof in medicine PAH, NLRP3, CYP11B2 ALDH1A1 1562/4885HPGD 251/4885KDM4E 2925/4885
US-20200062763-A1 URAT1 INHIBITOR AND USE THEREOF SLC14A1, SLC10A6, SLC10A1 ALDH1A1 356/4885HPGD 2933/4885KDM4E 4224/4885
US-10875865-B2 URAT1 inhibitor and use thereof SLC14A1, SLC10A6, SLC10A1 ALDH1A1 356/4885HPGD 2933/4885KDM4E 4224/4885
US-20200347070-A1 HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF IN MEDICINE PAH, NLRP3, CYP11B2 ALDH1A1 1562/4885HPGD 251/4885KDM4E 2925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.